Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Desmopressin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1A known ✓ | P37288 | 5/20 | 0.96 |
| ▸ | AVPR2 known ✓ | P30518 | 3/20 | 0.96 |
| ▸ | AVPR1B known ✓ | P47901 | 3/20 | 0.96 |
| ▸ | OXTR | P30559 | 8/20 | 0.96 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.96 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Desmopressin SCHEMBL1172203 | 0.99 | OXTR (0.97) | OXTRAVPR1AAVPR2AVPR1BPTGS1 | |
| Desmopressin SCHEMBL29935850 | 0.99 | OXTR (0.97) | OXTRAVPR1AAVPR2AVPR1BPTGS1 | |
| Desmopressin SCHEMBL22511 | 0.98 | OXTR (1.00) | OXTRAVPR1AAVPR2AVPR1BPTGS1 | |
| Desmopressin SCHEMBL29387302 | 0.98 | OXTR (1.00) | OXTRAVPR1AAVPR2AVPR1BPTGS1 | |
| Desmopressin SCHEMBL29454824 | 0.98 | OXTR (1.00) | OXTRAVPR1AAVPR2AVPR1BPTGS1 | |
| Vasopressin SCHEMBL29530914 | 0.93 | AVPR1A (0.97) | OXTRAVPR1AAVPR2AVPR1BPTGS1 | |
| SCHEMBL31061295 | 0.92 | AVPR2 (0.87) | OXTRAVPR1AAVPR2AVPR1BPTGS1 | |
| Desmopressin SCHEMBL4642385 | 0.92 | OXTR (0.81) | OXTRAVPR1AAVPR2AVPR1BPTGS1 | |
| Desmopressin SCHEMBL28142694 | 0.92 | OXTR (0.81) | OXTRAVPR1AAVPR2AVPR1BPTGS1 | |
| Desmopressin SCHEMBL347838 | 0.92 | OXTR (0.81) | OXTRAVPR1AAVPR2AVPR1BPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12576125-B2 | Desmopressin oral compositions | TULEX PHARMACEUTICALS INC. (US) | 2026-03-17 | — | — | US | disclosed |
| EP-4687859-A2 | DESMOPRESSIN ORAL COMPOSITIONS | TULEX PHARMACEUTICALS, INC. (US) | 2026-02-11 | — | — | EP | disclosed |
| US-12466851-B2 | Manufacture of disulfide bonded peptides | BACHEM HOLDING AG (CH) | 2025-11-11 | — | — | US | disclosed |
| US-20250281567-A1 | DESMOPRESSIN ORAL COMPOSITIONS | TULEX PHARMACEUTICALS INC. | 2025-09-11 | — | — | US | disclosed |
| US-12343372-B2 | Desmopressin oral compositions | TULEX PHARMACEUTICALS INC. (US) | 2025-07-01 | — | — | US | disclosed |
| US-20250090623-A1 | DESMOPRESSIN ORAL COMPOSITIONS | TULEX PHARMACEUTICALS INC. | 2025-03-20 | — | — | US | disclosed |
| US-12214010-B2 | Desmopressin oral compositions | TULEX PHARMACEUTICALS INC. (US) | 2025-02-04 | — | — | US | disclosed |
| US-20240335501-A1 | DESMOPRESSIN ORAL COMPOSITIONS | TULEX PHARMACEUTICALS INC. | 2024-10-10 | — | — | US | disclosed |
| WO-2024211393-A2 | DESMOPRESSIN ORAL COMPOSITIONS | TULEX PHARMACEUTICALS INC. (US) | 2024-10-10 | — | — | WO | disclosed |
| CN-118078835-A | Therapeutic agent for nocturnal frequency | 杏林制药株式会社 | 2024-05-28 | — | — | CN | disclosed |
| WO-2015001134-A2 | METHOD FOR PREPARATION OF DESMOPRESSIN | LONZA LTD (CH) | 2015-01-08 | — | — | WO | disclosed |
| WO-2015001134-A2 | METHOD FOR PREPARATION OF DESMOPRESSIN | LONZA LTD (CH) | 2015-01-08 | — | — | WO | disclosed |
| US-7927613-B2 | Pharmaceutical co-crystal compositions | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-04-19 | — | — | US | disclosed |
| EP-2288345-A1 | PSYCHO-PHARMACEUTICALS | University College Dublin National University Of Ireland, Dublin (IE) | 2011-03-02 | — | — | EP | disclosed |
| US-20110034565-A1 | PSYCHO-PHARMACEUTICALS | UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN (IE) | 2011-02-10 | — | — | US | disclosed |
| US-7790905-B2 | Pharmaceutical propylene glycol solvate compositions | MCNEIL-PPC, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| WO-2009128058-A1 | PSYCHO-PHARMACEUTICALS | UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN et al (IE) | 2009-10-22 | — | — | WO | disclosed |
| EP-1991212-A1 | MODULATION OF NEUROGENESIS BY NOOTROPIC AGENTS | Braincells, Inc. (US) | 2008-11-19 | — | — | EP | disclosed |
| US-20070244143-A1 | MODULATION OF NEUROGENESIS BY NOOTROPIC AGENTS | BRAINCELLS, INC (US) | 2007-10-18 | — | — | US | disclosed |
| WO-2007104035-A1 | MODULATION OF NEUROGENESIS BY NOOTROPIC AGENTS | BRAINCELLS, INC. (US) | 2007-09-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250090623-A1 | DESMOPRESSIN ORAL COMPOSITIONS | AVPR2, AVPR1A, AVPR1B | AVPR1A 2/4885AVPR2 1/4885AVPR1B 3/4885 |
| US-12343372-B2 | Desmopressin oral compositions | AVPR2, AVPR1A, AVPR1B | AVPR1A 2/4885AVPR2 1/4885AVPR1B 3/4885 |
| US-20110034565-A1 | PSYCHO-PHARMACEUTICALS | PNMT, HTR3C, HTR5A | AVPR1A 322/4885AVPR2 356/4885AVPR1B 185/4885 |
| US-20240335501-A1 | DESMOPRESSIN ORAL COMPOSITIONS | AVPR2, AVPR1A, AVPR1B | AVPR1A 2/4885AVPR2 1/4885AVPR1B 3/4885 |
| US-20070244143-A1 | MODULATION OF NEUROGENESIS BY NOOTROPIC AGENTS | GAP43, BDNF, DCX | AVPR1A 1398/4885AVPR2 1629/4885AVPR1B 1228/4885 |
| US-12576125-B2 | Desmopressin oral compositions | AVPR2, F8, AVPR1B | AVPR1A 4/4885AVPR2 1/4885AVPR1B 3/4885 |
| US-20250281567-A1 | DESMOPRESSIN ORAL COMPOSITIONS | AVPR2, AVPR1A, AVPR1B | AVPR1A 2/4885AVPR2 1/4885AVPR1B 3/4885 |
| US-12214010-B2 | Desmopressin oral compositions | AVPR2, AVPR1A, AVPR1B | AVPR1A 2/4885AVPR2 1/4885AVPR1B 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.